Soquelitinib Market Summary

Key Factors Driving Soquelitinib Growth

1. Significant Unmet Need in Relapsed/Refractory PTCL

PTCL is an aggressive and rare subtype of non-Hodgkin lymphoma associated with poor outcomes and limited effective treatment options. Corvus notes that there are currently no fully approved therapies supported by randomized Phase 3 data specifically for relapsed/refractory PTCL, creating an attractive opportunity for differentiated therapies. The lack of effective treatment options increases the likelihood of rapid physician adoption if Phase III data are positive.

2. Encouraging Clinical Efficacy and Survival Data

Soquelitinib has demonstrated promising efficacy in heavily pretreated T-cell lymphoma patients. In the Phase I/Ib trial, patients treated with the selected 200 mg BID dose achieved a median progression-free survival (PFS) of 6.2 months and median overall survival (OS) of 28.1 months, substantially exceeding the historical survival expectations for relapsed PTCL patients. Several complete responses remained durable for more than two years. Earlier analyses also showed objective responses in approximately one-third of evaluable patients and a median duration of response exceeding 14 months.

3. Registrational Phase III Trial Underway

A major value inflection point is the ongoing randomized registrational Phase III trial comparing soquelitinib against standard-of-care chemotherapy in relapsed/refractory PTCL. Successful completion of this study could support regulatory submissions and commercial launch. Corvus initiated the trial in September 2024, and enrollment is ongoing. Positive Phase III data would significantly expand investor and physician confidence in the drug.

4. Regulatory Advantages: Orphan Drug and Fast Track Designations

The FDA granted both Orphan Drug Designation and Fast Track Designation for soquelitinib in relapsed/refractory PTCL. In addition, the European Medicines Agency granted orphan designation in 2025. These designations provide regulatory incentives, potential market exclusivity benefits, fee reductions, and opportunities for accelerated regulatory interactions, all of which may shorten development timelines and improve commercial prospects.

5. First-in-Class ITK Inhibition Mechanism

Soquelitinib is positioned as a potential first-in-class selective ITK inhibitor. Unlike conventional cytotoxic therapies, ITK inhibition modulates T-cell differentiation, enhances Th1 immune responses, suppresses Th2/Th17 signaling, and may improve anti-tumor immunity. Published preclinical studies in npj Drug Discovery suggest potential utility not only in lymphoma but also in combination immunotherapy and inflammatory diseases. This differentiated mechanism could support broad lifecycle expansion opportunities.

Soquelitinib Recent Developments

• In June 2026, Corvus Pharmaceuticals announced that it participated in a new USD 13.5 million financing for Angel Pharmaceuticals Ltd. (Angel Pharma), the Company’s collaboration partner in China. Corvus co-founded Angel Pharma in 2020 to enable the clinical development and commercialization of its pipeline in China as well as the development of other novel drugs. Corvus is Angel Pharma’s largest shareholder and is investing USD 5 million in the current financing.
• In May 2026, Corvus Pharmaceuticals announced the presentation of final data from its randomized, blinded, placebo-controlled Phase I trial evaluating soquelitinib in patients with moderate-to-severe atopic dermatitis in two oral sessions at the Society for Investigative Dermatology (SID) Annual Meeting. The first oral presentation covers soquelitinib’s immunologic and clinical activity, and the second late-breaking oral presentation covers its potential to provide prolonged drug-free remissions.

“Soquelitinib Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Soquelitinib for potential indication like Anaplastic large cell lymphoma, Follicular lymphoma, Peripheral T-cell lymphoma, Atopic dermatitis, Autoimmune Lymphoproliferative Syndrome, Asthma, Autoimmune disorders, Hidradenitis suppurativa, Hypersensitivity, and Solid tumours in the 7MM. A detailed picture of Soquelitinib’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Soquelitinib for potential indications. The Soquelitinib market report provides insights about Soquelitinib’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Soquelitinib performance, future market assessments inclusive of the Soquelitinib market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Soquelitinib sales forecasts, along with factors driving its market.

Soquelitinib Drug Summary

Soquelitinib is an investigational, orally administered small-molecule inhibitor targeting IL-2–inducible T-cell kinase (ITK), a key signaling enzyme in the T-cell receptor pathway that regulates T-cell activation and differentiation. By selectively inhibiting ITK, Soquelitinib is designed to modulate immune responses by shifting T-cell signaling away from pro-inflammatory Th2/Th17-driven activity while preserving or enhancing cytotoxic T-cell and NK-cell–mediated anti-tumor immunity, making it a potential therapeutic candidate in both oncology and immune-mediated diseases. It has been most prominently explored in relapsed or refractory T-cell lymphomas and certain autoimmune conditions, where immune dysregulation plays a central role. Administered orally in clinical studies, Soquelitinib’s development has focused on achieving immune modulation without broad immunosuppression, aiming to balance anti-tumor efficacy with tolerability. Early-stage clinical data have suggested manageable safety and pharmacodynamic activity consistent with ITK pathway engagement, though it remains under clinical investigation and is not yet approved for commercial use. The report provides Soquelitinib’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Soquelitinib Market Report

The report provides insights into:

• A comprehensive product overview including the Soquelitinib MoA, description, dosage and administration, research and development activities in potential indication like Anaplastic large cell lymphoma, Follicular lymphoma, Peripheral T-cell lymphoma, Atopic dermatitis, Autoimmune Lymphoproliferative Syndrome, Asthma, Autoimmune disorders, Hidradenitis suppurativa, Hypersensitivity, and Solid tumours.
• Elaborated details on Soquelitinib regulatory milestones and other development activities have been provided in Soquelitinib market report.
• The report also highlights Soquelitinib‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Soquelitinib market report also covers the patents information, generic entry and impact on cost cut.
• The Soquelitinib market report contains current and forecasted Soquelitinib sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Soquelitinib market report also features the SWOT analysis with analyst views for Soquelitinib in potential indications.

Methodology

The Soquelitinib market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Soquelitinib Analytical Perspective by DelveInsight

• In-depth Soquelitinib Market Assessment

This Soquelitinib sales market forecast report provides a detailed market assessment of Soquelitinib for potential indication like Anaplastic large cell lymphoma, Follicular lymphoma, Peripheral T-cell lymphoma, Atopic dermatitis, Autoimmune Lymphoproliferative Syndrome, Asthma, Autoimmune disorders, Hidradenitis suppurativa, Hypersensitivity, and Solid tumours in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Soquelitinib sales data uptil 2034.

• Soquelitinib Clinical Assessment

The Soquelitinib market report provides the clinical trials information of Soquelitinib for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Soquelitinib Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Soquelitinib Market Potential & Revenue Forecast

• Projected market size for the Soquelitinib and its key indications
• Estimated Soquelitinib sales potential (Soquelitinib peak sales forecasts)
• Soquelitinib Pricing strategies and reimbursement landscape

Soquelitinib Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Soquelitinib Market positioning compared to existing treatments
• Soquelitinib Strengths & weaknesses relative to competitors

Soquelitinib Regulatory & Commercial Milestones

• Soquelitinib Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Soquelitinib Clinical Differentiation

• Soquelitinib Efficacy & safety advantages over existing drugs
• Soquelitinib Unique selling points

Soquelitinib Market Report Highlights

• In the coming years, the Soquelitinib market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Soquelitinib companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Soquelitinib’s dominance.
• Other emerging products for Anaplastic large cell lymphoma, Follicular lymphoma, Peripheral T-cell lymphoma, Atopic dermatitis, Autoimmune Lymphoproliferative Syndrome, Asthma, Autoimmune disorders, Hidradenitis suppurativa, Hypersensitivity, and Solid tumours are expected to give tough market competition to Soquelitinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Soquelitinib in potential indications.
• Analyse Soquelitinib cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Soquelitinib sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Soquelitinib in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Soquelitinib? How strong is Soquelitinib’s clinical and commercial performance?
• What is Soquelitinib’s clinical trial status in each individual indications such as Anaplastic large cell lymphoma, Follicular lymphoma, Peripheral T-cell lymphoma, Atopic dermatitis, Autoimmune Lymphoproliferative Syndrome, Asthma, Autoimmune disorders, Hidradenitis suppurativa, Hypersensitivity, and Solid tumours and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Soquelitinib Manufacturers?
• What are the key designations that have been granted to Soquelitinib for potential indications? How are they going to impact Soquelitinib’s penetration in various geographies?
• What is the current and forecasted Soquelitinib market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Soquelitinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Soquelitinib for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Soquelitinib? What is the duration of therapy and what are the geographical variations in cost per patient?